• 華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬協(xié)和醫(yī)院胰腺外科中心(武漢430022);

目的 觀察無(wú)水乙醇腹腔神經(jīng)叢阻滯術(shù)對(duì)晚期胰腺癌頑固性疼痛的鎮(zhèn)痛效果、并發(fā)癥發(fā)生及患者生存質(zhì)量的影響。方法 選取2001年1月至2005年9月61例晚期胰腺癌伴頑固性疼痛及消化道梗阻無(wú)法行根治手術(shù)的患者,在行姑息性手術(shù)的同時(shí),行腹腔神經(jīng)叢無(wú)水乙醇阻滯治療,觀察術(shù)后3個(gè)月內(nèi)疼痛緩解、生存質(zhì)量評(píng)分(KPS)的變化及不良反應(yīng)。結(jié)果 治療后1周內(nèi)全部患者頑固性疼痛癥狀明顯緩解 (P<0.05), KPS評(píng)分顯著提高 (P<0.05)。隨診3個(gè)月,術(shù)后86.5% (45/52) 患者無(wú)痛或僅輕度疼痛,治療過(guò)程中和治療后未發(fā)生嚴(yán)重并發(fā)癥。結(jié)論 無(wú)水乙醇腹腔神經(jīng)叢阻滯治療晚期胰腺癌頑固性疼痛能較好地緩解其癥狀,改善患者生存質(zhì)量,近期療效確切,安全性高。

引用本文: 熊炯炘,黃鵬,陶京,王春友,吳河水. 腹腔神經(jīng)叢阻滯術(shù)治療晚期胰腺癌頑固性疼痛的臨床研究. 中國(guó)普外基礎(chǔ)與臨床雜志, 2006, 13(5): 515-517. doi: 復(fù)制

1.  Wanebo HJ, Vezeridis MP. Pancreatic carcinoma in perspective. A continuing challenge [J]. Cancer, 1996; 78(3 Supple)∶580.
2.  Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas [J]. Ann Surg, 1996; 223(5)∶506.
3.  孫 燕, 顧慰萍. 癌癥三階梯止痛指導(dǎo)原則 [M]. 北京: 北京醫(yī)科大學(xué)出版社, 2000∶12~16.
4.  Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial [J]. J Clin Oncol, 1997; 15(6) ∶2403.
5.  World Health Organization. Handbook for reporting results of cance treatment. World Health Organization. Genvae, 1976∶16-21.
6.  Kita Y, Tanaka T, Yoshida S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model [J]. Vaccine, 2005; 23 (17-18)∶2132.
7.  王春友. 重視胰腺癌分期評(píng)估及綜合治療的科學(xué)抉擇 [J]. 中國(guó)實(shí)用外科雜志, 2004; 24( 5) ∶259.
8.  Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3 000 patients with pancreatic carcinoma [J]. Cancer, 1999; 85(6)∶1261.
9.  王 平, 陶 凡, 鄭漢光. 腹腔神經(jīng)阻滯用于晚期癌性疼痛的療效觀察 [J]. 中國(guó)疼痛醫(yī)學(xué)雜志, 2003; 9(2)∶117.
10.  Popiela T, Kedra B, Sierzega M, et al. Surgical palliation for pancreatic cancer. The 25-year experience of a single reference centre [J]. Zentralbl Chir, 2002; 127(11)∶965.
  1. 1.  Wanebo HJ, Vezeridis MP. Pancreatic carcinoma in perspective. A continuing challenge [J]. Cancer, 1996; 78(3 Supple)∶580.
  2. 2.  Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas [J]. Ann Surg, 1996; 223(5)∶506.
  3. 3.  孫 燕, 顧慰萍. 癌癥三階梯止痛指導(dǎo)原則 [M]. 北京: 北京醫(yī)科大學(xué)出版社, 2000∶12~16.
  4. 4.  Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial [J]. J Clin Oncol, 1997; 15(6) ∶2403.
  5. 5.  World Health Organization. Handbook for reporting results of cance treatment. World Health Organization. Genvae, 1976∶16-21.
  6. 6.  Kita Y, Tanaka T, Yoshida S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model [J]. Vaccine, 2005; 23 (17-18)∶2132.
  7. 7.  王春友. 重視胰腺癌分期評(píng)估及綜合治療的科學(xué)抉擇 [J]. 中國(guó)實(shí)用外科雜志, 2004; 24( 5) ∶259.
  8. 8.  Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3 000 patients with pancreatic carcinoma [J]. Cancer, 1999; 85(6)∶1261.
  9. 9.  王 平, 陶 凡, 鄭漢光. 腹腔神經(jīng)阻滯用于晚期癌性疼痛的療效觀察 [J]. 中國(guó)疼痛醫(yī)學(xué)雜志, 2003; 9(2)∶117.
  10. 10.  Popiela T, Kedra B, Sierzega M, et al. Surgical palliation for pancreatic cancer. The 25-year experience of a single reference centre [J]. Zentralbl Chir, 2002; 127(11)∶965.